Luther A Bartelt
Overview
Explore the profile of Luther A Bartelt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andermann T, Brown D, Holowka T, Bartelt L, Serody J, Armistead P, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae760.
PMID: 39817037
Background: Antimicrobial resistance is a global public health emergency. Patients undergoing hematopoietic stem cell transplantation (HCT) are at increased risk for severe infections with multidrug-resistant (MDR) organisms, although more data...
2.
Gutierrez L, Vielot N, Herrera R, Reyes Y, Toval-Ruiz C, Blandon P, et al.
PLoS Negl Trop Dis
. 2024 Nov;
18(11):e0012230.
PMID: 39527625
Background: Giardia lamblia is an intestinal protozoan estimated to cause ~200 million symptomatic infections annually, mainly in children in low- and middle-income countries associated with intestinal damage, increased permeability, and...
3.
Bhatt A, Arnold J, Awoniyi M, Sun S, Feijoli Santiago V, Coskuner D, et al.
Gut Microbes
. 2024 Nov;
16(1):2421623.
PMID: 39501168
Undernutrition in children commonly disrupts the structure and function of the small intestinal microbial community, leading to enteropathies, compromised metabolic health, and impaired growth and development. The mechanisms by which...
4.
Henderson H, Wohl D, Fischer W, Bartelt L, van Duin D, Agil D, et al.
J Antimicrob Chemother
. 2024 Feb;
79(4):859-867.
PMID: 38380946
Background: In the USA, nirmatrelvir/ritonavir is authorized for the treatment of mild-to-moderate COVID-19 in patients at least 12 years of age, at high risk for progression to severe COVID-19. Objectives:...
5.
Bhatt A, Arnold J, Awoniyi M, Sun S, Feijoli Santiago V, Henrique Quintela P, et al.
bioRxiv
. 2024 Feb;
PMID: 38328247
Undernutrition in children commonly disrupts the structure and function of the small intestinal microbial community, leading to enteropathies, compromised metabolic health, and impaired growth and development. The mechanisms by which...
6.
Markmann A, Bhowmik D, Jiang B, Van Hoy M, Wang F, Hou Y, et al.
bioRxiv
. 2023 Jul;
PMID: 37398270
The ongoing COVID-19 pandemic has caused millions of deaths and the continued emergence of new variants suggests continued circulation in the human population. In the current time of vaccine availability...
7.
Giallourou N, Arnold J, Rogawski McQuade E, Awoniyi M, Becket R, Walsh K, et al.
Nat Commun
. 2023 May;
14(1):2840.
PMID: 37202423
Giardia lamblia (Giardia) is among the most common intestinal pathogens in children in low- and middle-income countries (LMICs). Although Giardia associates with early-life linear growth restriction, mechanistic explanations for Giardia-associated...
8.
Holowka T, van Duin D, Bartelt L
JAC Antimicrob Resist
. 2023 Apr;
5(2):dlad051.
PMID: 37102119
The global burden of infection from MDR organisms (MDROs) disproportionately affects children residing in low- and middle-income countries and those with increased healthcare exposure. These populations have high rates of...
9.
Rausch E, Vemuri K, Anderman T, Daniels L, Fabricio J, Lachiewicz A, et al.
Open Forum Infect Dis
. 2022 Dec;
9(12):ofac591.
PMID: 36570967
No abstract available.
10.
Root H, Gilleskie M, Lu C, Gilmore A, Evans M, Nelson B, et al.
PLoS One
. 2022 Dec;
17(12):e0277707.
PMID: 36480499
Amidst the therapeutic void at the onset of the COVID-19 pandemic, a critical mass of scientific and clinical interest coalesced around COVID-19 convalescent plasma (CCP). To date, the CCP literature...